MedWatch

Orphazyme gets another annual report extension approved

Biotech firm Orphazyme is pushing back the release of its annual report for 2021 once again, allowing the company to proceed with the ongoing in-court restructuring.

Photo: Orphazyme/PR

Biotech company Orphazyme has been granted another new deadline for the release of its full-year 2021 report, the company has announced in a press release on Tuesday.

Upon request, the Danish Business Authority has approved an extension to the deadline for annual report’s filing, which follows the initiation of Orphazyme’s in-court restructuring proceedings.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Related articles

Latest news

See all jobs